. Author manuscript; available in PMC: 2022 Apr 11.

Published in final edited form as: Ann Breast Surg. 2021 Sep 30;5:30. doi: 10.21037/abs-20-96

Table 5.

Manufacturer-specific global risk estimates of BIA-ALCL

Manufacturer	Textured implant type	Texturization method	Global risk
Allergan	Biocell	Salt loss	1:602 to 1:8,500
Mentor	Siltex	Negative imprint	1:6,703 to 1:86,029
Sientra		Heat vulcanization	TBD
Silimed	Polyurethane	Foam-coated	1:2,832

Currently 5 US Sientra BIA-ALCL cases to date. Availability of Sientra implants has not reached the average follow up for disease development and represents less than 5% of US market share. BIA-ALCL, breast implant-associated anaplastic large cell lymphoma.